Literature DB >> 2987487

5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: pharmacological characterization and effects of antidepressants.

D A Kendall, S R Nahorski.   

Abstract

The ability of 5-hydroxytryptamine (5-HT) and related agonists to stimulate hydrolysis of inositol phospholipids was examined in rat cerebral cortex slices using a direct assay which involves prelabeling with [3H]inositol and assaying [3H]inositol phosphates in the presence of lithium. 5-HT agonists stimulated [3H]inositol phosphate accumulation in a dose-related but biphasic manner and only the high-affinity component of the dose-response curve was sensitive to antagonists. This response to 5-HT was blocked potently by ketanserin and other putative 5-HT2 antagonists but the overall pattern of apparent drug affinities was inconsistent with that seen at 5-HT2 sites labeled with [3H]ketanserin in cortical membranes. Pretreatment of slices with the alkylating antagonist phenoxybenzamine reduced the inositol phospholipid response to 5-HT to a greater extent than the suppression of [3H]ketanserin binding. Similarly, chronic but not acute treatment of rats with the antidepressants iprindole and imipramine resulted in a greater loss of 5-HT-induced inositol phospholipid hydrolysis than specific [3H]ketanserin binding. However, the effect of antidepressants was agonist-specific in that neither alpha-1 adrenoceptor nor muscarinic receptor stimulation were altered by acute or chronic treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987487

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  36 in total

1.  Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors.

Authors:  P A Pierce; J Y Kim; S J Peroutka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

2.  Imipramine-induced changes in 5-HT2 receptor sites and inositoltrisphosphate levels in rat brain.

Authors:  M N Subhash; S Jagadeesh
Journal:  Neurochem Res       Date:  1997-09       Impact factor: 3.996

3.  Central serotonin receptors: effector systems, physiological roles and regulation.

Authors:  P J Conn; E Sanders-Bush
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Tricyclic antidepressants, mianserin, and ouabain stimulate inositol phosphate formation in vitro in rat cortical slices.

Authors:  N N Osborne
Journal:  Neurochem Res       Date:  1988-02       Impact factor: 3.996

5.  Regulation of rat cortical 5-hydroxytryptamine2A receptor-mediated electrophysiological responses by repeated daily treatment with electroconvulsive shock or imipramine.

Authors:  Gerard J Marek
Journal:  Eur Neuropsychopharmacol       Date:  2008-02-21       Impact factor: 4.600

6.  Electroconvulsive treatment: effects on phospholipase C activity and GTP binding activity in rat brain.

Authors:  A Nishida; H Kaiya; T Tohmatsu; S Wakabayashi; Y Nozawa
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 7.  Binding sites for brain trace amines.

Authors:  T V Nguyen; A V Juorio
Journal:  Cell Mol Neurobiol       Date:  1989-09       Impact factor: 5.046

8.  The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons.

Authors:  A Dumuis; M Sebben; J Bockaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

9.  Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system.

Authors:  E Sanders-Bush; M Breeding; K Knoth; M Tsutsumi
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  GABAB receptors, monoamine receptors, and postsynaptic inositol trisphosphate-induced Ca2+ release are involved in the induction of long-term potentiation at visual cortical inhibitory synapses.

Authors:  Y Komatsu
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.